Pacira BioSciences, Inc. (PCRX) - Dilution Analysis
Visualizing historical and potential share dilution over time
Dilution Analysis
Risk Assessment Details
Summary
PCRX currently has 40.5M outstanding shares. with minimal authorized share overhang for future dilution. The company has minimally diluted shareholders by 0.31% over the past 2 years.
Share Structure Timeline
Historical Data Points
| Date | Event | Outstanding | Supply |
|---|---|---|---|
| Apr 30, 2026 |
10-Q filing | 40.5M shares outstanding |
40M | 0 |
| Aug 05, 2025 |
10-Q filing | 45.5M shares outstanding |
45M | 0 |
| May 08, 2025 |
10-Q filing | 46.3M shares outstanding |
46M | 0 |
| Feb 27, 2025 |
10-K filing | 46.2M shares outstanding |
46M | 0 |
| Nov 06, 2024 |
10-Q filing | 46.1M shares outstanding |
46M | 0 |
| Jul 30, 2024 |
10-Q filing | 46.2M shares outstanding |
46M | 0 |
| May 14, 2024 |
8-K filing: Pacira BioSciences, Inc. issued $250.0 million principal amount of 2.125% Convertible Senior Notes due 2029 and granted the Initial Purchasers an option to purchase an additional $37.5 million aggregate principal amount of the Notes on the same terms and conditions, which option was exercised in full by the Initial Purchasers on May 10, 2024 and also repurchased 837,240 shares of the Company's Common Stock for approximately $25.0 million. ($25.0M proceeds) |
46M | 0 |
| May 07, 2024 |
10-Q filing | 46.5M shares outstanding |
46M | 0 |
| Feb 29, 2024 |
10-K filing | 46.2M shares outstanding |
46M | 0 |
| Nov 02, 2023 |
10-Q filing | 46.4M shares outstanding |
46M | 0 |
| Aug 02, 2023 |
10-Q filing | 46.1M shares outstanding |
46M | 0 |
| May 03, 2023 |
10-Q filing | 45.9M shares outstanding |
46M | 0 |
| Feb 28, 2023 |
10-K filing | 45.5M shares outstanding |
46M | 0 |
| Nov 03, 2022 |
10-Q filing | 45.8M shares outstanding |
46M | 0 |
| Aug 03, 2022 |
10-Q filing | 45.5M shares outstanding |
46M | 0 |
| May 04, 2022 |
10-Q filing | 44.9M shares outstanding |
45M | 0 |
| Feb 28, 2022 |
10-K filing | 44.3M shares outstanding |
44M | 0 |
| Nov 03, 2021 |
10-Q filing | 44.5M shares outstanding |
44M | 0 |
| Aug 03, 2021 |
10-Q filing | 44.1M shares outstanding |
44M | 0 |
| May 04, 2021 |
10-Q filing | 43.8M shares outstanding |
44M | 0 |
| Mar 01, 2021 |
10-K filing | 43.7M shares outstanding |
44M | 0 |
| Oct 30, 2020 |
10-Q filing | 42.9M shares outstanding |
43M | 0 |
| Aug 06, 2020 |
10-Q filing | 42.2M shares outstanding |
42M | 0 |
| Jul 10, 2020 |
8-K filing: Pacira BioSciences, Inc. issued $350 million of 0.750% Convertible Senior Notes due 2025 in a private placement, with an additional $52.5 million option exercised, and repurchased $185.0 million of its 2.375% convertible senior notes due 2022 for approximately $211.1 million in cash. ($389.9M proceeds) |
42M | 0 |
| May 07, 2020 |
10-Q filing | 42.0M shares outstanding |
42M | 0 |
| Feb 21, 2020 |
10-K filing | 41.5M shares outstanding |
42M | 0 |